Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140023/S034

Roche cobas KRAS Mutation Test

Roche Molecular Systems, Inc. · Decision date Nov 4, 2026

MEDTECHLEDGER EXPLANATIONP140023/S034

What did the FDA approve?

On 2026-11-04, FDA recorded an approval decision (APPR) for P140023/S034, a Special (Immediate Track) PMA supplement to Roche Molecular Systems, Inc. The supplement covers updates to hazard information in the product labeling for the cobas® DNA Sample Preparation Kit, which is a component of the cobas® KRAS Mutation Test, cobas® BRAF V600 Mutation Test, and cobas® EFGR Mutation Test, v2.0. The recorded reason is a labeling change affecting indications, instructions, shelf life or tradename.

This action concerns labeling for a shared sample-preparation component rather than a new approval of the broader test system. The device category is a somatic gene mutation detection system, with Pathology as the listed specialty and product code OWD. The source record does not include the revised hazard text, the specific labeling sections changed, or supporting documents, so the content and clinical effect of the update remain unknown.

The title field names the KRAS test, while the statement also lists BRAF and EFGR tests; the record does not explain that difference. No efficacy, safety or patient-selection conclusions follow from this labeling action.

FDA approval order statement

Approval for updates to the hazard information on the product labeling for cobas DNA Sample Preparation Kit, a component of cobas KRAS Mutation Test, cobas BRAF V600 Mutation Test, and cobas EFGR Mutation Test, v2.0.
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Pathology
Decision date
Nov 4, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P140023/S034
Regulatory pathway
PMA supplement
Product code
OWD
Decision code
APPR
Decision date
Nov 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Somatic gene mutation detection system.

Product code
OWD
FDA device class
3

For the original device and its historical approval scope, see PMA P140023. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P140023 · Original PMA

    COBAS KRAS MUTATION TEST

  2. P140023/S034 received

    Application receipt date recorded by FDA.

  3. P140023/S033 · Related supplement

    cobas KRAS Mutation Test

  4. P140023/S034 · FDA decision

    Special (Immediate Track)

Timeline entries are records held by MedtechLedger for P140023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140023

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA approvalMay 7, 2015FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA

Explore the linked device profile

Other records with product code OWD

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
RochePMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
RochePMA supplementOct 27, 2026FDA
Roche Molecular System, Inc.PMA supplementOct 27, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Molecular Systems, Inc.

Headquarters
Not reported
Brand website
roche.com
FDA applicant address
4300 Hacienda Dr., Pleasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records